NCT04808453View on ClinicalTrials.gov

Phase I Study of CPI-300 in Patients With Advanced Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

December 15, 2023

Study Completion Date

December 15, 2023

Conditions
Advanced Tumors
Interventions
DRUG

CPI-300

CPI-300 will be administered via intravenous infusion on Day 1 of a 14-Day cycle

Trial Locations (4)

32746

Florida Cancer Specialists, Lake Mary

37203

Sarah Cannon Research Institute, Nashville

44106

University Hospitals Cleveland Medical Center, Cleveland

85258

Honor Health Research Institute, Scottsdale

Sponsors
All Listed Sponsors
lead

Coordination Pharmaceuticals, Inc.

INDUSTRY